Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Gruppo Oncologico del Nord-Ovest
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07407465CT.gov Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT04704661CT.gov Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab Deruxtecan (this asset) | Gruppo Oncologico del Nord-Ovest | P2 | B · 60 |
| Fluorouracilum | Merck Sharp & Dohme LLC | P3 | BBB |
| Irinotecan | Sun Yat-sen University | P3 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BBB |
| Cetuximab | Merck Sharp & Dohme LLC | P3 | BB |
| Nivolumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Floxuridine | City of Hope Medical Center | P2 | BB |
| Encorafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2/3 | BB |
+42 more in the Colon Adenocarcinoma cohort
Other indications for Trastuzumab Deruxtecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 75 |
| Breast Cancer | — | P4 | BB · 66 |
| Metastatic Malignant Neoplasm In The Brain | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab Deruxtecan in Colon Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-deruxtecan-colon-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →